EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

Ryan C Shean iD, Tracy I George, David P Ng

Cytometry Part B: Clinical Cytometry · 2026

DOI: 10.1002/cyto.b.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2026. Verfasst von Ryan C Shean und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Mast Cells, Flow Cytometry, Interleukin-3 Receptor alpha Subunit, Mastocytosis, Systemic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by immunohistochemistry (IHC) with prognostic implications. This study aims to characterize CD123 expression in SM by flow cytometry. We retrospectively analyzed 142 bone marrow samples from 79 SM patients (81 diagnostic samples) and 25 controls with normal MC immunophenotype. Flow cytometry was performed using a clinically validated 9‐color mast cell tube which included CD123. Data collected included SM subtype, clinical and laboratory features, MC burden, and marker expression. Statistical analyses were performed in R. CD123 was expressed on MCs in 91% of SM cases (ISM 92%, SM‐AHN 94%, SSM 100%, ASM 100%, MCL 50%). Median percentage of MCs positive for CD123 was 53.9% (IQR 8.1–83.4). Compared to prior IHC data (overall 64% positivity), flow cytometry demonstrated more cases with CD123 expression by MCs. No significant correlations were observed between CD123 expression and serum tryptase, KIT D816V allele burden, or MC burden. CD123 is frequently expressed on neoplastic MCs in SM by flow cytometry, across all subtypes. These findings support further investigation of CD123 as a therapeutic target and warrant correlation with IHC and clinical outcomes in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsFlow CytometryInterleukin-3 Receptor alpha SubunitMastocytosis, SystemicHumansFemaleMaleMiddle AgedImmunophenotypingAgedAdultRetrospective StudiesImmunohistochemistryAged, 80 and overProto-Oncogene Proteins c-kit

Stichwörter der Autor:innen

CD123flow cytometryimmunophenotypingmast cellssystemic mastocytosis

Substanzen

Interleukin-3 Receptor alpha SubunitIL3RA protein, humanProto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
  • Department of Hematopathology, ARUP Laboratories, Salt Lake City, Utah, USA.

ORCID-Profile: Ryan C Shean

Zitieren

APA

Shean, R. C., George, T. I., & Ng, D. P. (2026). Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.70023

Vancouver

Shean RC, George TI, Ng DP. Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry. Cytometry Part B: Clinical Cytometry. 2026. doi:10.1002/cyto.b.70023

BibTeX
@article{Shean2026,
  author = {Shean, Ryan C and George, Tracy I and Ng, David P},
  title = {Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2026},
  doi = {10.1002/cyto.b.70023}
}
Kostenlos starten →